Targeting the programmed cell death and programmed cell death ligand-1 (PD-1/PD-L1) axis has achieved unprecedented success in HCC, but it also faces great challenges, with its low remission rate still to be solved [10]. The gene discussed is CD274; the disease is hepatocellular carcinoma.